Compass Therapeutics (NASDAQ:CMPX) Cut to Sell at Wall Street Zen

Wall Street Zen downgraded shares of Compass Therapeutics (NASDAQ:CMPX) from a hold rating to a sell rating in a research report sent to investors on Saturday.

Several other research firms have also issued reports on CMPX. Raymond James Financial reiterated an “outperform” rating on shares of Compass Therapeutics in a report on Thursday, March 5th. Jefferies Financial Group reiterated a “buy” rating and set a $9.00 target price on shares of Compass Therapeutics in a report on Thursday, March 5th. Weiss Ratings restated a “sell (d-)” rating on shares of Compass Therapeutics in a research note on Monday, April 20th. William Blair restated an “outperform” rating on shares of Compass Therapeutics in a research note on Thursday, March 5th. Finally, Craig Hallum began coverage on Compass Therapeutics in a research note on Friday, February 13th. They issued a “buy” rating and a $15.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Compass Therapeutics has an average rating of “Moderate Buy” and an average target price of $14.20.

Compass Therapeutics Stock Performance

CMPX opened at $1.79 on Friday. Compass Therapeutics has a 52-week low of $1.61 and a 52-week high of $6.88. The firm has a market capitalization of $322.36 million, a PE ratio of -4.16 and a beta of 1.49. The business’s 50-day simple moving average is $5.46 and its 200 day simple moving average is $5.28.

Compass Therapeutics (NASDAQ:CMPX) last released its earnings results on Thursday, March 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.01. On average, research analysts forecast that Compass Therapeutics will post -0.41 earnings per share for the current year.

Institutional Trading of Compass Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the business. Suvretta Capital Management LLC raised its stake in Compass Therapeutics by 0.6% in the fourth quarter. Suvretta Capital Management LLC now owns 14,182,379 shares of the company’s stock valued at $76,159,000 after buying an additional 81,220 shares during the period. Vivo Capital LLC raised its stake in Compass Therapeutics by 57.9% in the third quarter. Vivo Capital LLC now owns 9,545,466 shares of the company’s stock valued at $33,409,000 after buying an additional 3,502,000 shares during the period. BVF Inc. IL raised its stake in Compass Therapeutics by 63.5% in the fourth quarter. BVF Inc. IL now owns 7,764,842 shares of the company’s stock valued at $41,697,000 after buying an additional 3,014,842 shares during the period. Vanguard Group Inc. grew its position in shares of Compass Therapeutics by 45.6% in the third quarter. Vanguard Group Inc. now owns 7,062,799 shares of the company’s stock valued at $24,720,000 after purchasing an additional 2,212,794 shares during the last quarter. Finally, State Street Corp grew its position in shares of Compass Therapeutics by 57.4% in the fourth quarter. State Street Corp now owns 4,890,525 shares of the company’s stock valued at $26,262,000 after purchasing an additional 1,784,012 shares during the last quarter. Institutional investors own 68.43% of the company’s stock.

About Compass Therapeutics

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.